ADCs are an exciting new approach to the development of antibody-based cancer theraputics. This workshop will look at the attributes of successful antigen targets and anti-tumor antibodies used in ADCs.
We will discuss the selection of different linkers and payloads in ADC development and the role of conjugation site and target antigen internalization for the optimization of ADCs in vitro and in vivo efficacy. Finally, an understanding of targeted and non-targeted toxicities in the safety assessment of ADCs as predicted by rodent and non-human primate studies will also be debated.
Use this masterclass to hone your current knowledge of these innovative platforms and learn how to avoid the common pitfalls.
Jagath Reddy Junutula joined Genentech, Inc. in 2001 and is currently a Group Leader in the Research and Early Development Division (gRED). He obtained his Ph.D. in 1997 from Indian Institute of Science, Bangalore, India. Jagath has extensive experience in protein engineering, molecular enzymology and the functional role of GTPases in the protein targeting and intracellular trafficking. He developed a novel THIOMAB technology platform to generate specific antibody-drug conjugates to improve the therapeutic utility of drugs. Working with several cross functional teams in discovery research, preclinical development and clinical manufacturing he gained knowledge and experience in moving antibodybased therapeutic molecules from discovery phase to IND.
Willy Solis, Scientist, Genentech
Dr. Solis is a board certified toxicologist with extensive experience in drug development from early discovery through clinical trials. He graduated with a Ph.D. in Molecular Toxicology in 2001 from the University of Cincinnati, Ohio. His post-doctoral training focused on cell cycle checkpoint regulation and oxidative stress. Following his academic training, he worked as a nonclinical safety and DMPK scientist at Sugen-Pharmacia and contributed to the development of kinase inhibitors for oncology indications. Over the past 5 years, Dr. Solis has worked at Genentech as a toxicology scientist in several antibody-drug conjugate (ADC) projects. He is an expert on ADC safety evaluation, linker-cytotoxic drug selection, characterization of antigen-dependent and antigen–independent ADC-related toxicities, and implementation of nonclinical toxicology programs to enable ADCs in the clinic. He has authored multiple nonclinical sections in regulatory documents (IND and CTA) and addressed ADC-related nonclinical safety questions or concerns with regulatory authorities. Dr. Solis also holds a leadership position in a multidisciplinary group of scientists developing novel ADCs for breast cancer.
Rapid advances through clinical trials of both SGN-35 and T-DM1 have rekindled the promise of antibody-drug conjugates. The best drug properties of antibodies and small molecultes are now being successfully combined into a single drug entity. Although the current generation of ADCs show much clinical promise, the next generation of ADCs will utilize site-specific coupling chemistries mediated through protein engineering. This will not only maintain the specificity and potency described above but will improve the ADC half-life, safey and quality.
Topics to be covered include:
Intrinsic or enhanced antibody-mediated cytotoxicity
Linker characteristics and options
Potency expectations in vitro and in vivo in ADC development
Attendees will learn how to incorporate the current state of the art approaches to create more potent antibodies and ADCs. This workshop will benefit scientists that are new to the ADC field as well as those that have been practising the art for several years.